Psychopharmacology
May 2010
Robert A Battisti, Steven Roodenrys, Stuart J Johnstone et al.
The endogenous cannabinoid system is sensitive to the introduction of exogenous cannabinoids such as delta-9-tetrahydrocannabinol, which are known to impact upon memory functioning. We sought to examine the impact of chronic cannabis use upon memory-related brain function via examination of the subsequent memory effect (SME) of the event-related potential (ERP). The SME is predictive of recall...
Journal of the American Academy of Child and Adolescent Psychiatry
April 14, 2010
Gerry Jager, Robert I Block, Maartje Luijten et al.
Objective: Early-onset cannabis use has been associated with later use/abuse, mental health problems (psychosis, depression), and abnormal development of cognition and brain function. During adolescence, ongoing neurodevelopmental maturation and experience shape the neural circuitry underlying complex cognitive functions such as memory and executive control. Prefrontal and temporal regions are...
Psychopharmacology
April 2010
Marcello Solinas, Gianluigi Tanda, Carrie E Wertheim et al.
Although delta-9-tetreahydrocannabinol (THC)-induced elevations in accumbal dopamine levels are believed to play an important role in the abuse-related effects of cannabis, little direct evidence has been provided that the dopaminergic system is involved in the psychotropic effects of THC. The objective of this study is to investigate whether drugs activating or blocking the dopaminergic system...
Journal of Psychoactive Drugs
March 2010
Beth M Anderson, Matthew Rizzo, Robert I Block et al.
In the United States, one in six teenagers has driven under the influence of marijuana. Driving under the influence of marijuana and alcohol is equally prevalent, despite the fact that marijuana use is less common than alcohol use. Much of the research examining the effects of marijuana on driving performance was conducted in the 1970s and led to equivocal findings. During that time, few...
Journal of Psychopharmacology
March 2010
Lineke Zuurman, Christine Roy, R C Schoemaker et al.
CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist. Inhibition of THC-induced effects by AVE1625 was observed on Visual Analogue Scales 'alertness', 'feeling high',...
PLoS One
February 10, 2010
Clara Touriño, Andreas Zimmer, Olga Valverde
55 citations
The majority of MDMA (ecstasy) recreational users also consume cannabis. Despite the rewarding effects that both drugs have, they induce several opposite pharmacological responses. MDMA causes hyperthermia, oxidative stress and neuronal damage, especially at warm ambient temperature. However, THC, the main psychoactive compound of cannabis, produces hypothermic, anti-inflammatory and...
Drug and Alcohol Dependence
February 9, 2010
Joanna S Zeiger, Brett C Haberstick, Robin P Corley et al.
Introduction: Marijuana is the most commonly used illicit drug among adolescents. Marijuana use induces both psychological and physiological responses, which can be interpreted by an individual in a variety of ways (i.e. subjective effects). We have examined subjective effects in adolescent, young adult community, and clinical populations to determine how patterns of use may be predicted by an...
Journal of Neurochemistry
February 2010
Ni Fan, Hongwei Yang, Jian Zhang et al.
Chronic use of marijuana impairs synaptic plasticity and cognitive function. However, the molecular mechanisms by which marijuana alters long-term synaptic plasticity are largely unknown. Here, we show that repeated in vivo exposures to Delta9-THC for 7 consecutive days significantly impaired hippocampal long-term potentiation (LTP) of excitatory glutamatergic synaptic transmission. The...
Behavioural Brain Research
January 20, 2010
Haitham Amal, Lilach Fridman-Rozevich, Roey Senn et al.
A single administration of an extremely low dose (0.002 mg/kg) of Delta9-tetrahydrocannabinol (THC; the psychoactive ingredient of marijuana) to ICR mice induced long-term cognitive deficits that lasted for at least 5 months. The behavioral deficits were detected by several tests that evaluated different aspects of memory and learning, including spatial navigation and spatial and non-spatial...
Pharmacology
2010
Matthew Goddard, Paul F Smith, John C Ashton
Previous studies have suggested panic induced by cannabinoids may be potentiated by concurrently using selective serotonin reuptake inhibitors. We therefore tested for panic and anxiety-related behaviour in rats coadministered with the selective serotonin reuptake inhibitor fluoxetine hydrochloride and the CB1 agonist delta9-tetrahydrocannabinol. Although each drug alone elicited behaviours...